A Placebo-Controlled Augmentation Trial of Prazosin for Combat Trauma PTSD
Annual rept. 1 Jun 2010-31 May 2011
SEATTLE INST FOR BIOMEDICAL AND CLINICAL RESEARCH SEATTLE WA
Pagination or Media Count:
This study consists of a 14-week, two parallel group, randomized placebo controlled trial to evaluate the efficacy and tolerability of the alpha-1 adrenergic antagonist, prazosin, for reducing trauma nightmares and sleep disturbance and improving global function and sense of well-being, in 210 OIF and OEF combat-exposed returnees with PTSD and persistent trauma-related nightmares and disrupted sleep. A secondary aim is to assess efficacy of prazosin for reducing total PTSD symptoms, reducing symptoms of depression, improving quality of life, and reducing alcohol craving.
- Medicine and Medical Research